WEC
DGX icon

Winslow Evans & Crocker’s Quest Diagnostics DGX Stock Holding History

Winslow Evans & Crocker’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-70
Closed -$8K – 1189
2019
Q1 		$8K Buy
+70
New +$6.07K ﹤0.01% 848
2018
Q2 		– Sell
-22
Closed -$2.11K – 1134
2018
Q1 		$2.11K Hold
22
– – ﹤0.01% 1020
2017
Q4 		$2.07K Sell
22
-110
-83% -$10.4K ﹤0.01% 1031
2017
Q3 		$12.4K Buy
132
+5
+4% +$531 ﹤0.01% 776
2017
Q2 		$14.1K Sell
127
-1
-0.8% -$106 ﹤0.01% 839
2017
Q1 		$12.5K Hold
128
– – ﹤0.01% 839
2016
Q4 		$11.8K Buy
+128
New +$11K ﹤0.01% 841

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
FMI
Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Winslow Evans & Crocker's DGX Position: Q2 2019 in Review

Winslow Evans & Crocker sold out of Quest Diagnostics (DGX) in Q2 2019, closing a stake of 70 shares — an estimated $8K sold.

Winslow Evans & Crocker first reported a position in DGX in Q4 2016 and held it in 7 quarters. The position peaked at $14.1K in Q2 2017. 654 funds tracked by Wall St. Rank hold DGX as of Q2 2019.

  • Winslow Evans & Crocker reported no remaining Quest Diagnostics position as of Q2 2019 after selling out during the quarter.
  • Winslow Evans & Crocker sold 70 Quest Diagnostics shares in Q2 2019, an estimated $8K.
  • Winslow Evans & Crocker first reported a position in Quest Diagnostics in Q4 2016 and held it in 7 quarters.
  • Winslow Evans & Crocker's Quest Diagnostics position peaked at $14.1K in Q2 2017.
  • 654 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2019.

Based on Winslow Evans & Crocker's 13F filing for Q2 2019, filed 19 Jul 2019.